<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is usually considered as incurable, but patient's outcome has been steadily improving over the last decade </plain></SENT>
<SENT sid="1" pm="."><plain>The introduction of anti-CD20 monoclonal antibodies represented a major step </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment of patients should take into account accurate staging results, symptoms related to <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, age and comorbidities </plain></SENT>
<SENT sid="3" pm="."><plain>Several options are still available for patients with localized or asymptomatic low risk disease, and randomized studies should be developed for those patients </plain></SENT>
<SENT sid="4" pm="."><plain>When a systemic therapy is needed, the combination of rituximab with a few of the available cytotoxic regimens clearly provides the best results </plain></SENT>
<SENT sid="5" pm="."><plain>Rituximab maintenance appears to further improve the progression-free interval </plain></SENT>
<SENT sid="6" pm="."><plain>Since most patients will likely survive for many years, the quality and duration of response as well as the short- and long-term side effects of the treatments should be carefully weighted during this prolonged therapeutic management </plain></SENT>
</text></document>